A quantitative universal NGS-based circulating tumor DNA assay for hepatoblastoma
Kahana-Edwin, S.; Torpy, J.; Cain, L. E.; Mullins, A.; McCowage, G.; Woodfield, S. E.; Vasudevan, S. A.; Shea, D. P. T.; Minoche, A. E.; Kummerfeld, S.; Goldstein, L. D.; Karpelowsky, J.
Show abstract
Driver mutations in CTNNB1 are a hallmark of hepatoblastoma and offer a common biomarker for a liquid biopsy approach based on the presence of CTNNB1 circulating tumor DNA (ctDNA). We developed and investigated the utility of a quantitative universal next-generation sequencing (NGS) ctDNA assay for hepatoblastoma (QUENCH) to detect CTNNB1 ctDNA and assessed the links between ctDNA and current clinical indicators/biomarkers in hepatoblastoma. Applied to patients with hepatoblastoma, we demonstrate quantitation of various variants including single base substitutions and deletions down to 0.3% variant allele frequency, with 65% sensitivity and 100% specificity at the patient level, to allow biopsy-free tumor genotyping and sensitive ctDNA quantitation. CtDNA positivity correlates with tumor burden and ctDNA levels correlate with macroscopic residual disease and treatment response, thus providing promising evidence for the utility of quantitative ctDNA detection in hepatoblastoma.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Clinical validation of Whole Genome Sequencing for routine cancer diagnostics 94%
- A Validated Functional Analysis of PALB2 Missense Variants for Use in Clinical Variant Interpretation 91%
- Optical Genome Mapping: Clinical Validation and Diagnostic Utility for Enhanced Cytogenomic Analysis of Hematological Neoplasms 91%
Similar papers in this journal
- Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing 94%
- Short and long-read genome sequencing methodologies for somatic variant detection; genomic analysis of a patient with diffuse large B-cell lymphoma 92%
- Genomic alterations and abnormal expression of APE2 in multiple cancers 92%
Similar papers in this journal
- Germline testing data validate inferences of mutational status for variants detected from tumor-only sequencing 92%
- Low abundance of circulating tumor DNA in localized prostate cancer 91%
- Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma 91%
Similar papers in this journal
- Combination of hotspot mutations with methylation and fragmentomic profiles to enhance Multi-Cancer Early Detection 94%
- Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis 92%
- Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel 90%
Similar papers in this journal
- Propagated circulating tumor cells uncovers the rople of NFκB and COP1 in metastasis 92%
- Tyrosyl-DNA phosphodiesterase 1 and topoisomerase I activities as predictive indicators for Glioblastoma susceptibility to genotoxic agents 92%
- Development of a Single Molecule Counting Assay to Differentiate Chromophobe Renal Cancer and Oncocytoma in Clinics 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.